This site is intended for healthcare professionals
Last reviewed dd mmm yyyy. Last edited dd mmm yyyy
6595 middle-aged men (age 45-64) with a mean cholesterol of 7.0 +/- 0.6 mmol were randomised to pravastatin 40 mg per day or placebo.
The average follow-up was 4.9 years.
Pravastatin altered serum lipids in the following manner:
The relative risks in the pravastatin group reduced by:
There was no significant excess in non-cardiovascular deaths in the pravastatin group.
Calculated - treating 1000 patients for 5 years - saves 7 deaths from CHD and 20 non-fatal MIs (1)
Primary prevention with pravastatin for 5 years continued to prevent coronary events in the following 10 years (2):